Durata Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2012, the company has rapidly established itself as a leader in developing innovative therapies for infectious diseases, particularly focusing on antibiotic resistance. With a commitment to addressing unmet medical needs, Durata has achieved significant milestones, including the successful launch of its flagship product, Dalvance (dalbavancin), which offers a unique, long-acting treatment option for skin infections. Operating primarily in the US and expanding its reach globally, Durata Therapeutics is recognised for its dedication to research and development, positioning itself at the forefront of the fight against resistant pathogens. The company’s strategic focus on high-quality, effective treatments has garnered notable achievements, solidifying its reputation within the healthcare community.
We don't have data for Durata Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company